Clinical Trial Detail

NCT ID NCT03562507
Title Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

renal cell carcinoma

Therapies

CEP-11981

CEP-11981 + Nivolumab

Age Groups: adult senior

No variant requirements are available.